Treatment of new onset type 1 diabetes with teplizumab: Successes and pitfalls in development

Expert Opinion on Biological Therapy

Volumn 14, Issue 3, 2014, Pages 377-385

  Vudattu, Nalini K ^a   Herold, Kevan C ^a  

^a YALE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; INSULIN; MONOCLONAL ANTIBODY; TEPLIZUMAB;

ANIMAL; DIABETES MELLITUS, TYPE 1; DISEASE COURSE; DRUG DEVELOPMENT; DRUG EFFECTS; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; PANCREAS ISLET BETA CELL; PROCEDURES; T LYMPHOCYTE; TREATMENT OUTCOME; TRENDS;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; DISEASE PROGRESSION; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOTHERAPY; INSULIN; INSULIN-SECRETING CELLS; T-LYMPHOCYTES; TREATMENT OUTCOME;

EID: 84894198208     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.881797     Document Type: Article

References (64)

1. CDC. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States. Center for Disease Control and Prevention, USA 2011.
2. Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. N Engl J Med 1986;314(21):1360-8
3. Herold KC, Vignali DA, Cooke A, Bluestone JA. Type 1 diabetes: translating mechanistic observations into effective clinical outcomes. Nat Rev Immunol 2013;13(4):243-56
4. Chatenoud L. Immune therapy for type 1 diabetes mellitus-what is unique about anti-CD3 antibodies? Nature reviews Endocrinol 2010;6(3):149-57
5. Bougneres PF, Landais P, Boisson C,et al. Limited duration of remission of insulin dependency in children with recent overt type I diabetes treated with low-dose cyclosporin. Diabetes 1990;39(10):1264-72
6. Parving HH, Tarnow L, Nielsen FS,et al. Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year followup study. Diabetes Care 1999;22(3):478-83
7. Silverstein J, Maclaren N, Riley W,et al. Immunosuppression with azathioprine and prednisone in recent-onset insulindependent diabetes mellitus. N Engl J Med 1988;319(10):599-604
8. Eisenbarth GS, Srikanta S, Jackson R,et al. Anti-thymocyte globulin and prednisone immunotherapy of recent onset type 1 diabetes mellitus. Diabetes Res 1985;2(6):271-6
9. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H,et al. Rituximab, Blymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361(22):2143-52
10. Orban T, Bundy B, Becker DJ,et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, doubleblind, placebo-controlled trial. Lancet 2011;378(9789):412-19
11. Rigby MR, DiMeglio LA, Rendell MS,et al. Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebocontrolled phase 2 trial. Lancet Diabetes Endocrinol 2013;1(4):284-94
12. Pescovitz MD, Greenbaum CJ, Bundy B,et al. B-lymphocyte depletion with rituximab and beta-cell function: twoyear results. Diabetes Care. 2013. [Epub ahead of print]
13. Moran A, Bundy B, Becker DJ,et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013;381(9881):1905-15
14. Agardh CD, Lynch KF, Palmer M,et al. 65 vaccination: 5 years of follow-up in a randomised dose-escalating study in adult-onset autoimmune diabetes. Diabetologia 2009;52(7):1363-8
15. Mastrandrea L, Yu J, BehrensT,et al. Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, doubleblind study. Diabetes Care 2009;32(7):1244-9
16. Roep BO, Solvason N, Gottlieb PA,et al. Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8(+) T cells in type 1 diabetes. Sci Transl Med 2013;5(191):191ra82
17. Chatenoud L, Primo J, Bach JF. CD3 antibody-induced dominant self tolerance in overtly diabetic NOD mice. J Immunol 1997;158(6):2947-54
18. You S, Leforban B, Garcia C,et al. Adaptive TGF-beta-dependent regulatory T cells control autoimmune diabetes and are a privileged target of anti-CD3 antibody treatment. Proc Natl Acad Sci USA 2007;104(15):6335-40
19. You S, Slehoffer G, Barriot S,et al. Unique role of CD4+CD62L+ regulatory T cells in the control of autoimmune diabetes in T cell receptor transgenic mice. Proc Natl Acad Sci USA 2004;101(Suppl 2):14580-5
20. Belghith M, Bluestone JA, Barriot S,et al. F-beta-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat Med 2003;9(9):1202-8
21. You S, Zuber J, Kuhn C,et al. Induction of allograft tolerance by monoclonal CD3 antibodies: a matter of timing. Am J Transplant 2012;12(11):2909-19
22. Penaranda C, Tang Q, Bluestone JA. Anti-CD3 therapy promotes tolerance by selectively depleting pathogenic cells while preserving regulatory T cells. J Immunol 2011;187(4):2015-22
23. Goto R, You S, Zaitsu M,et al. Delayed anti-CD3 therapy results in depletion of alloreactive T cells and the dominance of foxp3(+) CD4(+) graft infiltrating cells. Am J Transplant 2013;13(7):1655-64
24. Esplugues E, Huber S, Gagliani N,et al. Control of TH17 cells occurs in the small intestine. Nature 2011;475(7357):514-18
25. Waldron-Lynch F, Henegariu O, Deng S,et al. Teplizumab induces human gut-tropic regulatory cells in humanized mice and patients. Sci Transl Med 2012;4(118):118ra12
26. Cosimi AB, Colvin RB, Burton RC,et al. Use of monoclonal antibodies to T-cell subsets for immunologic monitoring and treatment in recipients of renal allografts. N Engl J Med 1981;305(6):308-14
27. Hooks MA, Wade CS, Millikan WJ Jr. Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation. Pharmacotherapy 1991;11(1):26-37
28. Chatenoud L, Baudrihaye MF, Chkoff N,et al. Restriction of the human in vivo immune response against the mouse monoclonal antibody OKT3. J Immunol 1986;137(3):830-8
29. Chatenoud L, Ferran C, Legendre C,et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990;49(4):697-702
30. Smith KG, Austyn JM, Hariri G,et al. T cell activation by anti-T3 antibodies: comparison of IgG1 and IgG2b switch variants and direct evidence for accessory function of macrophage Fc receptors. Eur J Immunol 1986;16(5):478-86
31. Parren PW, Warmerdam PA, Boeije LC,et al. Characterization of IgG FcRmediated proliferation of human T cells induced by mouse and human anti-CD3 monoclonal antibodies. Identification of a functional polymorphism to human IgG2 anti-CD3. J Immunol 1992;148(3):695-701
32. Vallhonrat H, Williams WW, Cosimi AB,et al. In vivo generation of C4d, Bb, iC3b, and SC5b-9 after OKT3 administration in kidney and lung transplant recipients. Transplantation 1999;67(2):253-8
33. Woodle ES, Thistlethwaite JR, Ghobrial IA,et al.3 F(ab)2 fragments- retention of the immunosuppressive properties of whole antibody with marked reduction in T cell activation and lymphokine release. Transplantation 1991;52(2):354-60
34. Cole MS, Stellrecht KE, Shi JD,et al. HuM291, a humanized anti-CD3 antibody, is immunosuppressive to T cells while exhibiting reduced mitogenicity in vitro. Transplantation 1999;68(4):563-71
35. Xu D, Alegre ML, Varga SS,et al. In vitro characterization of five humanized OKT3 effector function variant antibodies. Cell Immunol 2000;200(1):16-26
36. Daifotis AG, Koenig S, Chatenoud L, Herold KC. Anti-CD3 clinical trials in type 1 diabetes mellitus. Clin Immunol 2013;149(3):268-78
37. Hagopian W, Ferry RJ, Jr. Sherry N,et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: 2-year results from the randomized, placebocontrolled Protege trial. Diabetes 2013;62(11):3901-8
38. Woodle ES, Bluestone JA, Zivin RA,et al. Humanized, nonmitogenic OKT3 antibody, huOKT3 gamma(Ala- Ala): initial clinical experience. Transplant Proc 1998;30(4):1369-70
39. Utset TO, Auger JA, Peace D,et al. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 2002;29(9):1907-13
40. Herold KC, Hagopian W, Auger JA,et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346(22):1692-8.
41. Herold KC, Gitelman SE, Masharani U,et al. A single course of anti-CD3 monoclonal antibody hOKT3gamma1 (Ala-Ala) results in improvement in Cpeptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes. Diabetes 2005;54(6):1763-9
42. Herold KC, Gitelman S, Greenbaum C,et al. Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years. Clin Immunol 2009;132(2):166-73
43. Keymeulen B, Vandemeulebroucke E, Ziegler AG,et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352(25):2598-608
44. Keymeulen B, Walter M, Mathieu C,et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53(4):614-23
45. Sherry N, Hagopian W, Ludvigsson J,et al. Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebocontrolled trial. Lancet 2011;378(9790):487-97
46. Herold KC, Gitelman SE, Ehlers MR,et al. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62(11):3766-74
47. Herold KC, Gitelman SE, Willi SM,et al. Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial. Diabetologia 2013;56(2):391-400
48. Sherry NA, Kushner JA, Glandt M,et al. Effects of autoimmunity and immune therapy on beta-cell turnover in type 1 diabetes. Diabetes 2006;55(12):3238-45
49. Lebastchi J, Deng S, Lebastchi AH,et al. Immune therapy and beta-cell death in type 1 diabetes. Diabetes 2013;62(5):1676-80
50. Bisikirska B, Colgan J, Luban J,et al.R stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs. J Clin Invest 2005;115(10):2904-13
51. Ablamunits V, Bisikirska B, Herold KC. Acquisition of regulatory function by human CD8(+) T cells treated with anti- CD3 antibody requires TNF. Eur J Immunol 2010;40(10):2891-901
52. Ablamunits V, Henegariu O, Preston-Hurlburt P, Herold KC. NKG2A is a marker for acquisition of regulatory function by human CD8+ T cells activated with anti-CD3 antibody. Eur J Immunol 2011;41(7):1832-42
53. Ablamunits V, Bisikirska BC, Herold KC. Human regulatory CD8 T cells. Ann NY Acad Sci 2008;1150:234-8
54. Ablamunits V, Henegariu O, Hansen JB,et al. Synergistic reversal of type 1 diabetes in NOD mice with anti- CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012;61(1):145-54
55. Takiishi T, Korf H, Van Belle TL,et al. Reversal of autoimmune diabetes by restoration of antigen-specific tolerance using genetically modified Lactococcus lactis in mice. J Clin Invest 2012;122(5):1717-25
56. Sherry NA, Chen W, Kushner JA,et al. Exendin-4 improves reversal of diabetes in NOD mice treated with anti-CD3 monoclonal antibody by enhancing recovery of beta-cells. Endocrinology 2007;148(11):5136-44
57. Bresson D, Togher L, Rodrigo E,et al. Anti-CD3 and nasal proinsulin combination therapy enhances remission from recent-onset autoimmune diabetes by inducing Tregs. J Clin Invest 2006;116(5):1371-81
58. Palmer JP, Fleming GA, Greenbaum CJ,et al. C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve beta-cell function: report of an ADA workshop, 21-22 October 2001. Diabetes 2004;53(1):250-64
59. Steffes MW, Sibley S, Jackson M. Thomas W. beta-Cell function and the development of diabetes-related complications in the diabetes control and complications trial. Diabetes Care 2003;26(3):832-6
60. Stiller CR, Dupre J, Gent M,et al. Effects of cyclosporine immunosuppression in insulin-dependent diabetes mellitus of recent onset. Science 1984;223(4643):1362-7
61. Greenbaum CJ, Beam CA, Boulware D,et al. Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data. Diabetes 2012;61(8):2066-73
62. McClymont SA, Putnam AL, Lee MR,et al. Plasticity of human regulatory T cells in healthy subjects and patients with type 1 diabetes. J Immunol 2011;186(7):3918-26
63. Andris F, Van Mechelen M, De Mattia F,et al. Induction of T cell unresponsiveness by anti-CD3 antibodies occurs independently of co-stimulatory functions. Eur J Immunol 1996;26(5):1187-95
64. Andris F, Denanglaire S, de Mattia F,et al. Naive T cells are resistant to anergy induction by anti-CD3 antibodies. J Immunol 2004;173(5):3201-8